Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead company's Christopher McDonald
Cell & Gene: The Podcast
English - February 15, 2024 09:00 - 20 minutes - 14.4 MB - ★★★★★ - 35 ratingsLife Sciences Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
On this episode of Cell & Gene: The Podcast, Christopher McDonald, Global Head of Technical Operations at Kite, a Gilead company, talks to Host Erin Harris about Kite's recent FDA approval of manufacturing process change resulting in reduced median turnaround time for Yescarta. They talk through the most significant steps Kite took to reach this approval, lessons learned from having worked with the FDA, scaling up technologies for cell therapy manufacturing, and more.